摘要
目的通过监测神经元特异性烯醇化酶（NSE）的变化情况来探讨依达拉奉对重型颅脑损伤急性期患者的治疗效果。方法60例重型颅脑损伤急性期患者随机分为治疗组（30例）和对照组（30例），前者在常规治疗的基础上加用依达拉奉治疗，后者采用常规治疗，观察两组治疗前、治疗后1、3、5、7d血NSE变化情况及21d患者GCS评分情况。结果两组患者治疗后，NSE均明显下降（P〈0．05），治疗3d后NSE水平两组间比较差异有统计学意义（P〈0．05）；治疗21d后两组GCS评分比较差异有统计学意义（P〈0．05）；两组患者用药期间未见有严重不良反应发生。结论依达拉奉治疗重型颅脑损伤，可以降低患者外周血NSE水平，减轻脑细胞的损伤，不良反应少。
Objective To study curative effect of edaravone on acute severe brain injury through the observation of neuron-specific enolase（ that is：NSE） changes. Methods 60 severe brain injury patients were randomly assigned into the treatment group（ n = 30） and the control group （n = 30）. Besides the routine treatment, edaravone was used in the treatment group for 7 days. The control group received the same treatment except edaravone. NSE were measured in the two groups before the treatment and at 1st,3rd,5th,7th day after the treatment. GCS was evaluated at 21 days. Results Compared the NSE before treatment and after three days,they had significant difference（P 〈0. 05, also between the two groups and the GCS after 21 days. they had no significant adverse drug reactions during the two groups of patients with medication. Conclusion Edaravone for patients with severe brain injury has a better treatment effect,medication safety, fewer adverse reactions from the mechanism of NSE at acute phase.
出处
《中国基层医药》
CAS
2009年第2期199-200,共2页
Chinese Journal of Primary Medicine and Pharmacy
基金
广东省深圳市科研基金资助项目（200702053）
关键词
颅脑损伤
活性氧
磷酸丙酮酸水合酶
依达拉奉
Cranioeerebral trauma
Reactive oxygen species
Phosphopyruvate hydratase
Edaravone
